Efficacy and Safety Study to Compare Ibuprofen + Caffeine With Ibuprofen Alone in the Treatment of Headache

Headache Clinical Trial

Official title:

A Clinical Multicenter, Phase III, Randomized, Double-blind, Prospective and Comparative Trial to Evaluate the Efficacy and Safety of the Combination of Ibuprofen + Caffeine in the Treatment of Headache Attacks, Compared to Ibuprofen Alone.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01172405
• Other study ID #: IBU-CAF-01/09
• Status: Not yet recruiting
• Phase: Phase 3
• First received: July 28, 2010
• Last updated: July 28, 2010
• Start date: October 2010
• Est. completion date: October 2012

Study information

• Verified date: July 2010
• Source: Mantecorp Industria Quimica e Farmaceutica Ltd.
• Contact: Claudia Domingues
• Phone: +551151885237
• Email: cdomingues[@]mantecorp.com
• Is FDA regulated: No
• Health authority: Brazil: National Committee of Ethics in Research
• Study type: Interventional

Clinical Trial Summary

Based on established therapeutic effect of ibuprofen in the treatment of headache attacks, and the action of caffeine in promoting better results when combined with treatments of first choice in the treatment of headache, this study is designed to:

• evaluate the efficacy of therapy with ibuprofen + caffeine in headache patients compared to ibuprofen alone;

• evaluate the tolerability of the association ibuprofen + caffeine compared to ibuprofen alone.

The hypothesis is that the association is superior to treatment with ibuprofen alone in terms of efficacy, while maintaining good tolerability.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 144
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients with ability to read, understand and sign the IC;

• Patients with symptoms of frequent episodic tension headache, mild to moderate;

• Patients with symptoms of migraine with or without aura, of mild to moderate intensity;

• Patients who have had between two and five headache attacks in the last 30 days;

• Patients who accept the condition of ingesting less than three cups of coffee per day and / or reduce the intake of any beverage that contains caffeine;

• Patients who accept the condition not to drink any beverage that contains caffeine for 24 hours after drug administration.

• Patients able to understand and maintain the clinical protocol.

• Patients who started or changed prophylactic treatment for headache 30 days before inclusion.

• Female patients of childbearing age must agree to undergo pregnancy testing through urine.

Exclusion Criteria:

• Patients in whom headache began after 50 years of age;

• Patients with strong or disabling headaches;

• Patients with chronic daily headaches lasting up to 72 h or with cluster headaches not responsive to common analgesics;

• Patients with headaches occurring in 15 or more days per month;

• Patients with secondary headaches;

• Patients who overuse analgesics (acetylsalicylic acid up to 300 mg / day) or NSAIDs;

• Known hypersensitivity to components of both formulations of the drug test as the comparison;

• Known hepatic or renal diseases;

• Patients who are pregnant or intend to become pregnant or lactating;

• Patients with severe concomitant systemic diseases such as cancer, diabetes, congenital or acquired heart diseases, hematological diseases, convulsive disorders, autoimmune diseases, renal failure, severe infections, hormonal disorders, pulmonary disorders and peptic diseases;

• History of alcoholism or substance abuse.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Headache

Intervention

Drug:
• Ibuprofen plus caffeine
One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
• Ibuprofen
One or two tablets of ibuprofen 400 mg when presenting headache.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mantecorp Industria Quimica e Farmaceutica Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of study treatment compared with control to relieve headache symptoms.	The evaluation of efficacy will be determined based on comparison of the intensity of headache before and after initiation of treatment, using the Functional Disabling Scale. The opinion of the investigator will be established based on the Likert scale and duration of symptoms after the treatment will be checked as a measure of comparison between treatments in the study.	4 weeks	No
Secondary	Tolerability of study treatment compared with control to relieve headache symptoms.	Tolerability will be assessed by the investigator through the number of adverse events definitely related to study medication. This relationship will be defined by applying the Naranjo algorithm.	4 weeks	Yes